miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy

• Published in: Cancers Vol. 10; no. 9; p. 289
• Main Authors: Nagesh, Prashanth K B, Chowdhury, Pallabita, Hatami, Elham, Boya, Vijaya K N, Kashyap, Vivek K, Khan, Sheema, Hafeez, Bilal B, Chauhan, Subhash C, Jaggi, Meena, Yallapu, Murali M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 25.08.2018; MDPI AG
• Subjects: chemosensitivity and EMT; docetaxel; miR-205; prostate cancer; prostate cancer; miR-205; docetaxel; chemosensitivity and EMT
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers10090289

The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. Previous studies have shown that miR-205 negatively regulates prostate cancer cell proliferation, metastasis, and drug resistance. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of a viable nanoparticle platform to deliver miR-205 is highly sought. A novel magnetic nanoparticle (MNP)-based nanoplatform composed of an iron oxide core with poly(ethyleneimine)-poly(ethylene glycol) layer(s) was developed. An optimized nanoplatform composition was confirmed by examining the binding profiles of MNPs with miR-205 using agarose gel and fluorescence methods. The novel formulation was applied to prostate cancer cells for evaluating cellular uptake, miR-205 delivery, and anticancer, antimetastasis, and chemosensitization potentials against docetaxel treatment. The improved uptake and efficacy of formulations were studied with confocal imaging, flow cytometry, proliferation, clonogenicity, Western blot, q-RT-PCR, and chemosensitization assays. Our findings demonstrated that the miR-205 nanoplatform induces significant apoptosis and enhancing chemotherapeutic effects in prostate cancer cells. Overall, these study results provide a strong proof-of-concept for a novel nonviral-based nanoparticle protocol for effective microRNA delivery to prostate cancer cells.